Drug Trial Radar · NCT07824986
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
May 1, 2028
Study completion Jan 1, 2031
Sponsor
- Lead sponsor
- Vivace Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.
Conditions
- Pleural Mesothelioma
- Mesothelioma
Interventions
VT3989Drug
• 100 mg orally once daily for 2 weeks on treatment followed by 2 weeks off treatment (2W/2W) in each 4-week cycle
gemcitabineDrug
• 1,000 mg/m2 IV on Days 1 and 8 of each 3-week cycle, or per local prescribing information/institutional practice
VinorelbineDrug
• 25-30 mg/m2 IV on Days 1 and 8 of each 3-week cycle, or per local prescribing information/institutional practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Approximately 32-35 months after first randomization
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.